title: Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system.
abstract: Neuropeptides have been implicated in the psychopathology of stimulants of abuse. Neurotensin is a neuropeptide associated with the regulation of the nigrostriatal and mesolimbic dopamine pathways. In addition, the ventral tegmental area, a midbrain region implicated in the rewarding effects of most, if not all, addictive drugs, appears to be a particularly critical target for nicotine action. Because neurotensin has been linked with both mesolimbic and mesocortical dopamine function, we examined the impact of nicotine treatment on central nervous neurotensin systems by measuring changes in neurotensin tissue content because it has been shown that such changes reflect alterations in release and activity of this peptide system. Male Sprague-Dawley rats received multiple administrations of (+/-) nicotine 4.0 mg/kg/day (0.8 mg/kg, i.p.; 5 x 2-h intervals) in the presence or absence of selective dopamine receptor antagonists (dopamine D(1); SCH 23390 or dopamine D(2); eticlopride) or two doses of the non-selective nicotinic acetylcholine receptor antagonist (mecamylamine; 3.0 and 6.0 mg/kg, s.c.). The nicotine treatment significantly decreased neurotensin-like immunoreactivity content in the ventral tegmental area, as well as related regions such as prefrontal cortex, substantia nigra, and anterior striatal region 12-18 h after drug treatment, but not the nucleus accumbens. The nicotine-mediated decrease in the neurotensin-like immunoreactivity of the ventral tegmental area was selectively blocked by a specific dopamine D(2), but not a dopamine D(1), receptor antagonist, while mecamylamine attenuated at the low (3.0 mg/kg) and completely blocked at high (6.0 mg/kg) dose this nicotine effect. These findings with previous studies, suggest that nicotine-mediated dopamine release activates D(2) receptors which in turn increases neurotensin release, turnover and acutely reduces tissue levels in the ventral tegmental area and other limbic and basal ganglia structures.
authors: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA. mario.alburges@utah.edu
authors: Mario E
authors: ME
authors: Alburges
authors: Amanda J
authors: AJ
authors: Hoonakker
authors: Glen R
authors: GR
authors: Hanson
mesh_terms: D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects / Q000502:physiology; D001552:Benzazepines / Q000008:administration & dosage / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008297:Male; D008464:Mecamylamine / Q000008:administration & dosage / Q000494:pharmacology; D009479:Neuropeptides / Q000502:physiology; D009496:Neurotensin / Q000502:physiology*; D009538:Nicotine / Q000008:administration & dosage / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D012457:Salicylamides / Q000008:administration & dosage / Q000494:pharmacology; D013681:Tegmentum Mesencephali / Q000187:drug effects* / Q000502:physiology
chemical_list: D001552:Benzazepines; D065127:Dopamine D2 Receptor Antagonists; D009479:Neuropeptides; D018733:Nicotinic Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D012457:Salicylamides; C031644:neurotensin-like immunoreactivity; D009496:Neurotensin; D008464:Mecamylamine; D009538:Nicotine; C045989:eticlopride
references: Neuropharmacology. 2005 Jan;48(1):72-9
references: 15617729
references: Synapse. 1994 Jan;16(1):36-44
references: 8134899
references: Brain Res. 1996 May 20;721(1-2):196-203
references: 8793101
references: Naunyn Schmiedebergs Arch Pharmacol. 1977 Mar;297(1):1-7
references: 193046
references: Synapse. 1996 Apr;22(4):369-81
references: 8867031
references: J Neurochem. 2002 Sep;82(5):1171-8
references: 12358764
references: J Pharmacol Exp Ther. 1985 Nov;235(2):544-50
references: 4057084
references: Brain Res. 2007 Jan 5;1127(1):90-8
references: 17113052
references: J Pharmacol Exp Ther. 2004 Oct;311(1):80-91
references: 15178698
references: J Neurochem. 2001 Feb;76(3):721-9
references: 11158242
references: J Pharmacol Exp Ther. 1994 Jul;270(1):192-7
references: 7913495
references: Br J Pharmacol. 2000 Nov;131(5):997-1003
references: 11053222
references: J Pharmacol Exp Ther. 1987 May;241(2):443-7
references: 3572804
references: Anal Biochem. 1976 May 7;72:248-54
references: 942051
references: Eur J Neurosci. 2006 Jul;24(1):116-34
references: 16882012
references: Neuropharmacology. 2003 Sep;45(3):334-44
references: 12871651
references: Brain Res. 2000 Jun 9;867(1-2):157-64
references: 10837809
references: Neurochem Res. 1988 Apr;13(4):305-9
references: 2455873
references: Psychopharmacology (Berl). 1989;97(2):243-52
references: 2471221
references: Brain Res. 1989 May 8;486(2):357-63
references: 2471575
references: Neurosignals. 2004 May-Jun;13(3):114-21
references: 15067198
references: Eur J Pharmacol. 1989 Jan 24;160(1):23-30
references: 2714362
references: Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
references: 2899326
references: J Neurosci. 2006 Jan 18;26(3):723-30
references: 16421292
references: J Pharmacol Exp Ther. 2000 Oct;295(1):58-66
references: 10991961
references: Eur J Neurosci. 2006 Jul;24(1):188-96
references: 16882016
references: Eur J Pharmacol. 1988 Aug 9;153(1):1-9
references: 2905662
references: Eur J Neurosci. 2002 Jun;15(11):1810-8
references: 12081661
references: Nature. 1990 Sep 6;347(6288):72-6
references: 2144334
references: Ann N Y Acad Sci. 1992;668:165-72
references: 1361111
references: J Chem Neuroanat. 2005 Jul;30(1):34-44
references: 15975762
references: Brain Res. 1985 Dec 9;358(1-2):70-6
references: 4075132
references: Psychopharmacology (Berl). 2007 Feb;190(3):269-319
references: 16896961
references: Mol Psychiatry. 2003 Jan;8(1):50-9, 9
references: 12556908
references: Nature. 2005 Jul 7;436(7047):103-7
references: 16001069
references: Neuroreport. 1999 Mar 17;10(4):697-702
references: 10208533
references: Neuroscience. 1991;45(1):81-93
references: 1754070
references: J Biol Chem. 1988 Feb 5;263(4):1719-25
references: 3276675
references: Neurochem Res. 2002 Mar;27(3):253-61
references: 11958525
references: J Pharmacol Exp Ther. 1990 Nov;255(2):775-80
references: 2147039
references: Neurosci Lett. 2001 Jan 26;298(1):1-4
references: 11154821
references: J Physiol. 1994 Jan 1;474(1):119-29
references: 8014889
references: Neuropharmacology. 2006 Jun;50(8):1030-40
references: 16580026
references: Neuroscience. 2002;111(1):177-87
references: 11955721
references: Eur J Neurosci. 2005 Mar;21(5):1145-54
references: 15813924
references: Proc Natl Acad Sci U S A. 1988 Aug;85(15):5409-13
references: 3399498
references: Brain Res. 1994 Dec 5;665(2):237-44
references: 7895059
references: Brain Res Bull. 1997;42(3):211-9
references: 8995332
references: Brain Res. 2001 Jun 29;905(1-2):120-6
references: 11423086
references: Brain Res. 2006 Apr 26;1085(1):77-86
references: 16574078
references: Brain Res. 2003 Nov 21;991(1-2):222-31
references: 14575895
references: Psychopharmacology (Berl). 2005 Oct;182(2):297-304
references: 16010538
references: Eur J Pharmacol. 2003 Jan 1;458(1-2):111-8
references: 12498914
references: J Neurosci. 2001 Mar 1;21(5):1452-63
references: 11222635
references: Endocrinology. 2000 Oct;141(10):3623-9
references: 11014216
references: J Pharmacol Exp Ther. 1984 May;229(2):487-92
references: 6201607
references: Neuropsychopharmacology. 2005 May;30(5):871-9
references: 15637639
references: Eur J Pharmacol. 1989 Feb 7;160(3):409-12
references: 2565819
references: Brain Res. 1987 Feb 10;403(1):147-50
references: 3828807
references: Neuroscience. 2000;98(3):485-92
references: 10869842
references: Neurosci Lett. 2003 Sep 11;348(2):61-4
references: 12902018
references: Neurosci Lett. 1988 Nov 22;94(1-2):93-8
references: 3071750
references: Neuropsychopharmacology. 2007 Feb;32(2):450-7
references: 17091130
references: Biochem Pharmacol. 1985 Nov 15;34(22):4065-6
references: 4062976
references: Neuropsychopharmacology. 2007 Jan;32(1):35-42
references: 16710311
references: Neurochem Res. 2004 Sep;29(9):1779-92
references: 15453274
references: Peptides. 2000 Nov;21(11):1751-3
references: 11090931